Cellectis (NASDAQ:CLLS) Issues Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Cellectis (NASDAQ:CLLS) released its earnings results on Thursday. The biotechnology company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.04, Zacks reports. Cellectis had a negative return on equity of 82.92% and a negative net margin of 102.34%.The business had revenue of $6.90 million for the quarter, compared to analysts’ expectations of $11.05 million.

Cellectis Trading Up 5.6%

NASDAQ:CLLS traded up $0.15 during trading hours on Friday, reaching $2.84. The company’s stock had a trading volume of 24,095 shares, compared to its average volume of 16,107. The firm has a market capitalization of $284.97 million, a price-to-earnings ratio of -4.37 and a beta of 2.91. The firm has a 50-day simple moving average of $2.95 and a 200-day simple moving average of $3.48. Cellectis has a 1 year low of $2.35 and a 1 year high of $5.48. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.52 and a current ratio of 1.52.

Institutional Trading of Cellectis

Institutional investors have recently added to or reduced their stakes in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Cellectis by 228.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock worth $5,856,000 after buying an additional 3,284,409 shares during the period. Acadian Asset Management LLC lifted its stake in shares of Cellectis by 132.9% in the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 26,461 shares during the last quarter. Virtu Financial LLC purchased a new stake in Cellectis during the 3rd quarter valued at about $72,000. Citadel Advisors LLC purchased a new stake in Cellectis during the 3rd quarter valued at about $633,000. Finally, Millennium Management LLC boosted its holdings in Cellectis by 61.9% during the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 22,080 shares during the period. 63.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on CLLS. Citizens Jmp reaffirmed a “market outperform” rating and set a $8.00 price target on shares of Cellectis in a research note on Tuesday, April 14th. Barclays assumed coverage on Cellectis in a research report on Thursday, May 28th. They set an “overweight” rating and a $9.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cellectis in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $7.00.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.